Oncocyte Corp Elects New Directors, Reports Executive Compensation
Ticker: IMDX · Form: 8-K · Filed: May 31, 2024 · CIK: 1642380
Sentiment: neutral
Topics: board-of-directors, executive-compensation, governance
TL;DR
Oncocyte added two new board members and filed executive comp details.
AI Summary
On May 30, 2024, Oncocyte Corporation announced the election of Dr. Jonathan P. S. Farber and Mr. David E. Bear to its Board of Directors. Additionally, the company reported on compensatory arrangements for its named executive officers, though specific details of these arrangements were not provided in this filing.
Why It Matters
The addition of new directors can signal a shift in company strategy or governance, while updates on executive compensation are closely watched by investors for insights into management incentives.
Risk Assessment
Risk Level: medium — Changes in board composition and executive compensation can indicate internal shifts that may impact future performance and shareholder value.
Key Players & Entities
- Oncocyte Corporation (company) — Registrant
- Dr. Jonathan P. S. Farber (person) — Newly elected Director
- Mr. David E. Bear (person) — Newly elected Director
FAQ
Who were the individuals elected to Oncocyte Corporation's Board of Directors?
Dr. Jonathan P. S. Farber and Mr. David E. Bear were elected to the Board of Directors.
What was the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported was May 30, 2024.
What is Oncocyte Corporation's state of incorporation?
Oncocyte Corporation is incorporated in California.
What is the principal executive office address for Oncocyte Corporation?
The principal executive office is located at 15 Cushing, Irvine, California 92618.
What items of the 8-K are being reported by Oncocyte Corporation?
The filing reports on the Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; and Compensatory Arrangements of Certain Officers.
Filing Stats: 443 words · 2 min read · ~1 pages · Grade level 13.5 · Accepted 2024-05-31 16:05:31
Key Financial Figures
- $360,000 — ident and Chief Executive Officer, from $360,000 to $400,000, (ii) James Liu, the Compan
- $400,000 — ief Executive Officer, from $360,000 to $400,000, (ii) James Liu, the Company's Senior D
- $200,000 — terim Principal Financial Officer, from $200,000 to $207,000, and (iii) Ekkehard Schtz,
- $207,000 — pal Financial Officer, from $200,000 to $207,000, and (iii) Ekkehard Schtz, M.D., Ph.D.,
- $351,525 — e Company's Chief Science Officer, from $351,525 to $378,025. Each of the salary increas
- $378,025 — Chief Science Officer, from $351,525 to $378,025. Each of the salary increases is effect
Filing Documents
- form8-k.htm (8-K) — 33KB
- 0001493152-24-022193.txt ( ) — 200KB
- ocx-20240530.xsd (EX-101.SCH) — 3KB
- ocx-20240530_lab.xml (EX-101.LAB) — 33KB
- ocx-20240530_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ONCOCYTE CORPORATION Date: May 31, 2024 By: /s/ Joshua Riggs Joshua Riggs President and Chief Executive Officer